At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,117 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
In Brief
A Phase 3 clinical trial evaluating Galcanezumab and Placebo for Chronic Migraine. Completed, enrolled 1,117 participants across 117 sites in 13 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesArgentina, Canada, Czechia, Germany, Israel, Italy, Mexico, Netherlands, Puerto Rico, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartNov 2015
Primary CompletionMar 2017
Study CompletionJul 2021
TodayJul 2026
First PostedNov 25, 2015
Enrollment StartNov 30, 2015
Primary CompletionMar 16, 2017
Study CompletionJul 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.6 years ago
Interventions
Galcanezumabdrug
Administered SC
Placebodrug
Administered SC